var data={"title":"Anastrozole: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Anastrozole: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5646?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=anastrozole-patient-drug-information\" class=\"drug drug_patient\">see &quot;Anastrozole: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135534\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Arimidex</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135535\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>ACH-Anastrozole;</li>\n      <li>ACT-Anastrozole;</li>\n      <li>Apo-Anastrozole;</li>\n      <li>Arimidex;</li>\n      <li>Auro-Anastrozole;</li>\n      <li>Bio-Anastrozole;</li>\n      <li>JAMP-Anastrozole;</li>\n      <li>Mar-Anastrozole;</li>\n      <li>Med-Anastrozole;</li>\n      <li>Mint-Anastrozole;</li>\n      <li>Mylan-Anastrozole;</li>\n      <li>Nat-Anastrozole;</li>\n      <li>PMS-Anastrozole;</li>\n      <li>RAN-Anastrozole;</li>\n      <li>Riva-Anastrozole;</li>\n      <li>Sandoz-Anastrozole;</li>\n      <li>Taro-Anastrozole;</li>\n      <li>Teva-Anastrozole;</li>\n      <li>Zinda-Anastrozole</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135573\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Aromatase Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135538\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Breast cancer, advanced:</b> Postmenopausal females: Oral: 1 mg once daily; continue until tumor progression</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Breast cancer, early (adjuvant treatment):</b> Postmenopausal females: Oral: 1 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Duration of therapy:</i> The American Society of Clinical Oncology (ASCO) guidelines for Adjuvant Endocrine Therapy of Hormone-Receptor Positive Breast Cancer (Focused Update) recommend a maximum duration of 5 years of aromatase inhibitor (AI) therapy for postmenopausal women; AIs may be combined with tamoxifen for a total duration of up to 10 years of endocrine therapy. Refer to the guidelines for specific recommendations based on menopausal status and tolerability (Burstein 2014). In a phase III study with another AI (letrozole), treatment with an additional 5 years of AI therapy (for a total of 10 years of AI therapy) demonstrated a significantly improved rate of disease-free survival and a decreased risk of disease recurrence and contralateral breast cancer (when compared to placebo), although overall survival was not significantly different between groups and bone-related adverse events occurred more frequently with letrozole versus placebo (Goss 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Breast cancer, risk reduction (off-label use):</b> Postmenopausal females &ge;40 years: Oral: 1 mg once daily for 5 years (Cuzick 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Endometrial or uterine cancer, recurrent or metastatic (off-label use): </b>Oral: 1 mg once daily (Rose 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ovarian cancer, recurrent (off-label use): </b>Oral: 1 mg once daily until disease progression or unacceptable toxicity (del Carmen 2003)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135539\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135540\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135541\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Mild to moderate impairment or stable hepatic cirrhosis: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Severe hepatic impairment: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135511\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Arimidex: 1 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135497\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6884236\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">May be administered with or without food. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49104430\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]). </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules (NIOSH 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135512\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Breast cancer:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">First-line treatment of locally-advanced or metastatic breast cancer (hormone receptor-positive or unknown) in postmenopausal women</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adjuvant treatment of early hormone receptor-positive breast cancer in postmenopausal women</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25721921\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Endometrial or uterine cancers (recurrent or metastatic); Ovarian cancer (recurrent); Risk reduction for breast cancer in postmenopausal women</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6743663\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Anastrozole may be confused with anagrelide, letrozole</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Arimidex may be confused with Aromasin</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135504\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Vasodilatation (25% to 36%), ischemic heart disease (4%; 17% in patients with pre-existing ischemic heart disease), hypertension (2% to 13%), angina pectoris (2%; 12% in patients with pre-existing ischemic heart disease), edema (7% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Fatigue (19%), mood disorder (19%), headache (9% to 18%), pain (11% to 17%), depression (2% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Skin rash (6% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Hot flash (12% to 36%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Gastrointestinal distress (29% to 34%), nausea (11% to 20%), vomiting (8% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Weakness (13% to 19%), arthritis (17%), arthralgia (2% to 15%), back pain (10% to 12%), ostealgia (6% to 12%), osteoporosis (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Pharyngitis (6% to 14%), dyspnea (8% to 11%), increased cough (7% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Peripheral edema (5% to 10%), chest pain (5% to 7%), venous thrombosis (2% to 4%; including pulmonary embolism, thrombophlebitis, retinal vein thrombosis), myocardial infarction (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Insomnia (2% to 10%), dizziness (5% to 8%), paresthesia (5% to 7%), anxiety (2% to 6%), confusion (2% to 5%), drowsiness (2% to 5%), malaise (2% to 5%), nervousness (2% to 5%), carpal tunnel syndrome (3%), hypertonia (3%), cerebrovascular insufficiency (2%), lethargy (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Alopecia (2% to 5%), pruritus (2% to 5%), diaphoresis (1% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Hypercholesterolemia (9%), increased serum cholesterol (9%), weight gain (2% to 9%), increased gamma-glutamyl transferase (2% to 5%), weight loss (2% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Constipation (7% to 9%), diarrhea (7% to 9%), abdominal pain (6% to 9%), anorexia (5% to 8%), dyspepsia (7%), gastrointestinal disease (7%), xerostomia (4% to 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Mastalgia (2% to 8%), urinary tract infection (2% to 8%), pelvic pain (5% to 7%), vulvovaginitis (6%), vaginal dryness (1% to 5%), vaginal hemorrhage (1% to 5%), vaginal discharge (4%), vaginitis (4%), leukorrhea (2% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Lymphedema (10%), breast neoplasm (5%), neoplasm (5%), anemia (2% to 5%), leukopenia (2% to 5%), tumor flare (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hepatic: Increased serum alkaline phosphatase (2% to 5%), increased serum ALT (2% to 5%), increased serum AST (2% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infection: Infection (2% to 9%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Bone fracture (1% to 10%), arthrosis (7%),  myalgia (2% to 6%), neck pain (2% to 5%), pathological fracture (2% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ophthalmic: Cataract (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Flu-like symptoms (2% to 7%), sinusitis (2% to 6%), bronchitis (2% to 5%), rhinitis (2% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Accidental injury (2% to 10%), cyst (5%), fever (2% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Anaphylaxis, angioedema, cerebral infarction, cerebral ischemia, decreased bone mineral density, dermal ulcer, endometrial carcinoma, erythema multiforme, hepatitis, hepatomegaly, hypercalcemia, hypersensitivity angiitis (including anaphylactoid purpura [IgA vasculitis]), increased serum bilirubin, jaundice, joint stiffness, pulmonary embolism, retinal thrombosis, skin blister, skin lesion, Stevens-Johnson syndrome, tenosynovitis (stenosing), urticaria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135516\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Hypersensitivity to anastrozole or any component of the formulation; use in women who are or may become pregnant</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Lactating women</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135501\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Decreased bone mineral density: Due to decreased circulating estrogen levels, anastrozole is associated with a reduction in bone mineral density (BMD); decreases (from baseline) in total hip and lumbar spine BMD have been reported. Patients with preexisting osteopenia are at higher risk for developing osteoporosis (Eastell 2008). When initiating anastrozole treatment, follow available guidelines for bone mineral density management in postmenopausal women with similar fracture risk; concurrent use of bisphosphonates may be useful in patients at risk for fractures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypercholesterolemia: Elevated total cholesterol levels (contributed to by LDL cholesterol increases) have been reported in patients receiving anastrozole; use with caution in patients with hyperlipidemias. Cholesterol levels should be monitored/managed in accordance with current guidelines for patients with LDL elevations.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Plasma concentrations in patients with stable hepatic cirrhosis were within the range of concentrations seen in normal subjects across all clinical trials. Has not been studied in patients with severe hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ischemic disease: Patients with preexisting ischemic cardiac disease have an increased risk for ischemic cardiovascular events.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pregnancy: Use is contraindicated in women who are or may become pregnant.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Premenopausal women: Anastrozole offers no clinical benefit in premenopausal women with breast cancer.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135567\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Inhibits</b> CYP2C9 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135506\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8780&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: May diminish the therapeutic effect of Anastrozole.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methadone: Aromatase Inhibitors may increase the serum concentration of Methadone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tamoxifen: May decrease the serum concentration of Anastrozole.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135508\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">X (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135519\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies. Anastrozole is contraindicated in women who are or may become pregnant (may cause fetal harm if administered during pregnancy). Use in premenopausal women with breast cancer does not provide any clinical benefit.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20543963\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if anastrozole is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1878921\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bone mineral density; total cholesterol and LDL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Breast cancer risk reduction (off-label use): Bone mineral density at baseline, mammograms, and clinical breast exam at baseline and at least every 2 years (Cuzick, 2014)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135500\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Potent and selective nonsteroidal aromatase inhibitor. By inhibiting aromatase, the conversion of androstenedione to estrone, and testosterone to estradiol, is prevented, thereby decreasing tumor mass or delaying progression in patients with tumors responsive to hormones. Anastrozole causes an 85% decrease in estrone sulfate levels. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135515\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of estradiol reduction: 70% reduction after 24 hours; 80% after 2 weeks of therapy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration of estradiol reduction: 6 days </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Well absorbed; extent of absorption not affected by food</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding, plasma: 40% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Extensively hepatic (~85%) via N-dealkylation, hydroxylation, and glucuronidation; primary metabolite (triazole) inactive </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: ~50 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: ~2 hours without food; 5 hours with food </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces; urine (urinary excretion accounts for ~10% of total elimination, mostly as metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135518\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Anastrozole Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (30): $404.36</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Arimidex Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (30): $629.56</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135520\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>A-Dex (KR);</li>\n      <li>Agerdex (IE);</li>\n      <li>Aksastrol (UA);</li>\n      <li>Alozex (BR);</li>\n      <li>Altraz (IN);</li>\n      <li>Amidex (IE);</li>\n      <li>Anaccord (NZ);</li>\n      <li>Anaglob (LK);</li>\n      <li>Anamidex (ID);</li>\n      <li>Anarix (JO);</li>\n      <li>Anarom (PH);</li>\n      <li>Anaromat (RO);</li>\n      <li>Anastrol (AU, IL);</li>\n      <li>Anastroplex (PH);</li>\n      <li>Anatero (TH, UA);</li>\n      <li>Anatrole (NZ);</li>\n      <li>Anazo (LK, TW, VN);</li>\n      <li>Anazole (PH);</li>\n      <li>Ansuzole (MY);</li>\n      <li>Anzonat (SG);</li>\n      <li>Anzucia (LK);</li>\n      <li>Aremed (MT, TH, TW);</li>\n      <li>Aremed 1 (SG);</li>\n      <li>Arianna (AU);</li>\n      <li>Arimidex (AE, AR, AT, AU, BB, BD, BE, BF, BG, BH, BJ, BM, BO, BR, BS, BZ, CH, CI, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EC, EE, ES, ET, FI, FR, GB, GH, GM, GN, GR, GT, GY, HK, HN, HR, HU, ID, IE, IL, IS, IT, JM, JO, JP, KE, KR, LB, LK, LR, LT, LU, LV, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NI, NL, NO, NZ, PA, PE, PH, PK, PL, PR, PT, QA, RO, RU, SA, SC, SD, SE, SG, SI, SL, SN, SR, SV, TH, TN, TR, TT, TW, TZ, UG, UY, VE, VN, ZA, ZM, ZW);</li>\n      <li>Ariniq (PH);</li>\n      <li>Armotraz (JO);</li>\n      <li>Arymideks (UA);</li>\n      <li>Azonet (HR);</li>\n      <li>Femistra (LK);</li>\n      <li>Femizet (PH, TH);</li>\n      <li>Gondonar (AR, PY);</li>\n      <li>Leprofen (PY);</li>\n      <li>Madelen (JO);</li>\n      <li>Ozolan (RO);</li>\n      <li>Sananas (PH);</li>\n      <li>Trozolet (CL, EC, PY, UY, VE);</li>\n      <li>Trozolite (AR);</li>\n      <li>Vexal-A (PH);</li>\n      <li>Zolasatin (MX);</li>\n      <li>Zortex (LB)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Apo-Anastrozole [product monograph]. Toronto, Ontario: Apotex Inc., May 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Arimidex (anastrozole) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Burstein HJ, Prestrud AA, Seidenfeld J, et al, &ldquo;American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women with Hormone Receptor-Positive Breast Cancer,&rdquo; <i>J Clin Oncol</i>, 2010, 28(23):3784-96.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/20625130/pubmed\" target=\"_blank\" id=\"20625130\">20625130</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Burstein HJ, Temin S, Anderson H, et al.  Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. <i>J Clin Oncol</i>. 2014;32(21):2255-2269.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/24868023/pubmed\" target=\"_blank\" id=\"24868023\">24868023</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Buzdar AU, Robertson JF, Eiermann W, et al, &ldquo;An Overview of the Pharmacology and Pharmacokinetics of the Newer Generation Aromatase Inhibitors Anastrozole, Letrozole, and Exemestane,&rdquo; <i>Cancer</i>, 2002, 95(9):2006-16.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/12404296/pubmed\" target=\"_blank\" id=\"12404296\">12404296</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cuzick J, Sestak I, Baum M, et al, &ldquo;Effect of Anastrozole and Tamoxifen as Adjuvant Treatment for Early-Stage Breast Cancer: 10-Year Analysis of the ATAC Trial,&rdquo; <i>Lancet Oncol</i>, 2010, 11(12):1135-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/ 21087898/pubmed\" target=\"_blank\" id=\" 21087898\"> 21087898</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24333009\"></a>Cuzick J, Sestak I, Forbes JF, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. <i>Lancet</i>. 2014;383(9922):1041-1048.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/24333009/pubmed\" target=\"_blank\" id=\"24333009\">24333009</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    del Carmen MG, Fuller AF, Matulonis U, et al, &ldquo;Phase II Trial of Anastrozole in Women With Asymptomatic M&uuml;llerian Cancer,&rdquo; <i>Gynecol Oncol</i>, 2003, 91(3):596-602.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/14675683/pubmed\" target=\"_blank\" id=\"14675683\">14675683</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eastell R, Adams JE, Coleman RE, et al, &ldquo;Effect of Anastrozole on Bone Mineral Density: 5-Year Results From the Anastrozole, Tamoxifen, Alone or in Combination Trial 18233230,&rdquo; <i>J Clin Oncol</i>, 2008, 26(7):1051-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/18309940/pubmed\" target=\"_blank\" id=\"18309940\">18309940</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Forbes JF, Cuzick J, Buzdar A, et al, &ldquo;Effect of Anastrozole and Tamoxifen as Adjuvant Treatment for Early-Stage Breast Cancer: 100-month Analysis of the ATAC Trial,&rdquo; <i>Lancet Oncol</i>, 2008, 9(1):45-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/18083636/pubmed\" target=\"_blank\" id=\"18083636\">18083636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27264120\"></a>Goss PE, Ingle JN, Pritchard KI, et al. Extending aromatase-inhibitor adjuvant therapy to 10 years. <i>N Engl J Med</i>. 2016;375(3):209-219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/27264120/pubmed\" target=\"_blank\" id=\"27264120\">27264120</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jenkins VA, Ambroisine LM, Atkins L, et al, &ldquo;Effects of Anastrozole on Cognitive Performance in Postmenopausal Women: A Randomised, Double-Blind Chemoprevention Trial (IBIS II),&rdquo; <i>Lancet Oncol</i>, 2008, 9(10):953-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/18768369/pubmed\" target=\"_blank\" id=\"18768369\">18768369</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kaufmann M, Jonat W, Hilfrich J, et al, &ldquo;Improved Overall Survival in Postmenopausal Women With Early Breast Cancer After Anastrozole Initiated After Treatment With Tamoxifen Compared With Continued Tamoxifen: The ARNO 95 Study,&rdquo; <i>J Clin Oncol</i>, 2007, 25(19):2664-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/17563395/pubmed\" target=\"_blank\" id=\"17563395\">17563395</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kendall A, Dowsett M, Folkerd E, et al, &ldquo;Caution: Vaginal Estradiol Appears to be Contraindicated in Postmenopausal Women on Adjuvant Aromatase Inhibitors,&rdquo; <i>Ann Oncol</i>, 2006, 17(4):584-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/16443612/pubmed\" target=\"_blank\" id=\"16443612\">16443612</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Koberle D and Thurlimann B, &ldquo;Anastrozole: Pharmacological and Clinical Profile in Postmenopausal Women With Breast Cancer,&rdquo; <i>Expert Rev Anticancer Ther</i>, 2001, 1(2):169-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/12113022/pubmed\" target=\"_blank\" id=\"12113022\">12113022</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lester JE, Dodwell D, Purohit OP, et al, &ldquo;Prevention of Anastrozole-Induced Bone Loss With Monthly Oral Ibandronate During Adjuvant Aromatase Inhibitor Therapy for Breast Cancer,&rdquo; <i>Clin Cancer Res</i>, 2008, 14(19):6336-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/18829518/pubmed\" target=\"_blank\" id=\"18829518\">18829518</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lonning PE, Geisler J, and Dowsett M, &ldquo;Pharmacological and Clinical Profile of Anastrozole,&rdquo; <i>Breast Cancer Res Treat</i>, 1998, 49(Suppl 1):53-7.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lonning P, Pfister C, Martoni A, et al, &ldquo;Pharmacokinetics of Third-Generation Aromatase Inhibitors,&rdquo; <i>Semin Oncol</i>, 2003, 30(4 Suppl 14):23-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/14513434/pubmed\" target=\"_blank\" id=\"14513434\">14513434</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Osteoporosis Foundation, &ldquo;Clinician's Guide to Prevention and Treatment of Osteoporosis,&rdquo; Washington, DC, 2014. Available at  http://nof.org/files/nof/public/content/file/2791/upload/919.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Njar VC and Brodie AM, &ldquo;Comprehensive Pharmacology and Clinical Efficacy of Aromatase Inhibitors,&rdquo; <i>Drugs</i>, 1999, 58(2):233-55.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/10473018/pubmed\" target=\"_blank\" id=\"10473018\">10473018</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19932916\"></a>O'Cearbhaill R, Zhou Q, Iasonos A, et al. Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors. <i>Gynecol Oncol.</i> 2010;116(3):424-429.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/19932916/pubmed\" target=\"_blank\" id=\"19932916\">19932916</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rose PG, Brunetto VL, VanLe L, et al, &ldquo;A Phase II Trial of Anastrozole in Advanced Recurrent or Persistent Endometrial Carcinoma: A Gynecologic Oncology Group Study,&rdquo; <i>Gynecol Oncol</i>, 2000, 78(2):212-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/10926805/pubmed\" target=\"_blank\" id=\"10926805\">10926805</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report,&rdquo; <i>Circulation</i>, 2002, 106(25):3143-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/12485966/pubmed\" target=\"_blank\" id=\"12485966\">12485966</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 31, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Visvanathan K, Hurley P, Bantug E, et al. Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2013;31(23):2942-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/23835710/pubmed\" target=\"_blank\" id=\"23835710\">23835710</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Winer EP, Hudis C, Burstein HJ, et al, &ldquo;American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors as Adjuvant Therapy for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Status Report 2004,&rdquo; <i>J Clin Oncol</i>, 2005, 23(3):619-29.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/15545664/pubmed\" target=\"_blank\" id=\"15545664\">15545664</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8780 Version 157.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F135534\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F135535\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F135573\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F135538\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F135539\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F135540\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F135541\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F135511\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F135497\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F6884236\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49104430\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F135512\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25721921\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F6743663\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F135504\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F135516\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F135501\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F135567\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F135506\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F135508\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F135519\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20543963\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1878921\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F135500\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F135515\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F135518\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F135520\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8780|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=anastrozole-patient-drug-information\" class=\"drug drug_patient\">Anastrozole: Patient drug information</a></li></ul></div></div>","javascript":null}